No Data
Evolus Broadens International Presence With Launch of Nuceiva (Botulinum Toxin Type A) in Spain
Launching in one of the five largest aesthetic toxin injectable markets in Europe1 as part of the company's geographic expansion strategy Evolus to provide Nuceiva for direct order and delivery to Spanish
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 30,778
Evolus(EOLS.US) Officer Sells US$6.01 Million in Common Stock
$Evolus(EOLS.US)$ Officer MOATAZEDI DAVID sold 471.43K shares of common stock on Jun 4, 5, 6, 2024 at an average price of $12.7391 for a total value of $6.01 million.Source: Announcement What is state
Form 144 | Evolus(EOLS.US) Officer Proposes to Sell 2.54 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 6, $Evolus(EOLS.US)$ Officer MOATAZEDI DAVID intends to sell 200K shares of its common stock on Jun 6, with a total market value of approximately $2.54 million. MOATAZEDI
Evolus(EOLS.US) Director Sells US$97,203 in Common Stock
$Evolus(EOLS.US)$ Director Malik Vikram sold 7,500 shares of common stock on Jun 3, 2024 at an average price of $12.9604 for a total value of $97,203.Source: Announcement What is statement of changes
Form 144 | Evolus(EOLS.US) Officer Proposes to Sell 1.97 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 5, $Evolus(EOLS.US)$ Officer MOATAZEDI DAVID intends to sell 155.28K shares of its common stock on Jun 5, with a total market value of approximately $1.97 million. MOATAZ